|Toxiciy Grade:||4||City/State/Province:||San Antonio TX|
|Treatments:||Chemotherapy, Biologic therapy||Hospital:||Cancer Therapy and Research Center|
Patients: This Phase I study involved 20 patients with metastatic colorectal cancer.
Treatment: The treatment consisted of one biologic agent (oblimersen, which is an antisense oligonucleotide directed to the Bcl-2 mRNA) and one chemotherapeutic agent (irinotecan).
Toxicity: Grade 3-4 toxicities included neutropenia, thrombocytopenia, anemia, lymphopenia, and diarrhea.
Results: One patient experienced a partial response and 10 additional patients had stable disease lasting 2.5–10 months. Median survival was not reported.
Correspondence: Dr A. W. Tolcher